Analysts Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $26.25

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) have been assigned an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $26.25.

TARA has been the subject of a number of analyst reports. Oppenheimer increased their price target on Protara Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, May 20th. HC Wainwright reissued a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Wall Street Zen raised Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. JPMorgan Chase & Co. decreased their target price on Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Protara Therapeutics in a research report on Tuesday, March 10th.

Insider Activity

In other news, insider Jacqueline Zummo sold 22,598 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $5.26, for a total transaction of $118,865.48. Following the completion of the sale, the insider directly owned 95,961 shares of the company’s stock, valued at $504,754.86. This trade represents a 19.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 7.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. AIGH Capital Management LLC purchased a new position in shares of Protara Therapeutics during the first quarter valued at approximately $8,454,000. ADAR1 Capital Management LLC increased its stake in shares of Protara Therapeutics by 3,127.4% during the fourth quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company’s stock valued at $6,059,000 after buying an additional 1,101,576 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in shares of Protara Therapeutics during the fourth quarter valued at approximately $5,562,000. Janus Henderson Group PLC increased its stake in shares of Protara Therapeutics by 21.5% during the fourth quarter. Janus Henderson Group PLC now owns 5,141,616 shares of the company’s stock valued at $27,379,000 after buying an additional 910,285 shares during the period. Finally, Integral Health Asset Management LLC increased its stake in shares of Protara Therapeutics by 60.7% during the fourth quarter. Integral Health Asset Management LLC now owns 2,250,000 shares of the company’s stock valued at $11,992,000 after buying an additional 850,000 shares during the period. Institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Stock Performance

Protara Therapeutics stock opened at $3.98 on Monday. The stock has a market capitalization of $223.68 million, a price-to-earnings ratio of -2.97 and a beta of 1.45. Protara Therapeutics has a 52-week low of $2.77 and a 52-week high of $7.82. The stock’s 50 day moving average price is $4.78 and its two-hundred day moving average price is $5.44.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. On average, equities research analysts forecast that Protara Therapeutics will post -1.44 EPS for the current year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.